secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001785530-22-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q1 net loss $15.3M; Jazz Pharma license and $40M loan extend runway
--------------------------------------------------------------------------------

- Net loss of $15.3M in Q1 2022 vs. $7.4M year-ago; R&D expense rose to $10.9M from $4.8M.
- Cash and equivalents of $143.7M at March 31, 2022; plus Jazz $15M upfront and $20M loan tranche, runway through Q4 2023.
- Entered exclusive global license with Jazz for WTX-613; $15M upfront, up to $1.26B milestones plus mid-single-digit royalties.
- IND submissions for WTX-124 and WTX-330 on track; preclinical data presented at AACR 2022.
- Closed $40M term loan with Pacific Western Bank; $20M available upon two IND acceptances by March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000020/0001785530-22-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000020/howl-20220510.htm
  HTML page:      https://secwatch.observer/filing/0001785530-22-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer